Chuanliang X. Cui

Chuanliang X. Cui

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

Journal: BMC medicine

Published: January 20, 2026

Sonazoid-enhanced ultrasound for preoperative localization and characterization of sentinel lymph nodes in patients with cutaneous melanoma.

Sonazoid-enhanced ultrasound for preoperative localization and characterization of sentinel lymph nodes in patients with cutaneous melanoma.

Journal: European radiology

Published: November 28, 2025

Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy.

Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy.

Journal: Experimental hematology & oncology

Published: October 13, 2025

Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma.

Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 24, 2025

A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

Journal: Nature communications

Published: August 08, 2025

MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.

MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 31, 2025

Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.

Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.

Journal: Urologic oncology

Published: June 30, 2025

Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective Analysis.

Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective Analysis.

Journal: Cancer investigation

Published: May 23, 2025

Efficacy of radiotherapy combined with systemic therapy for retroperitoneal lymph node metastasis in upper tract urothelial carcinoma(UTUC) patients after radical nephroureterectomy.

Efficacy of radiotherapy combined with systemic therapy for retroperitoneal lymph node metastasis in upper tract urothelial carcinoma(UTUC) patients after radical nephroureterectomy.

Journal: World journal of surgical oncology

Published: May 18, 2025

Association between estimated cumulative LDL-C exposure and coronary artery disease severity and 2-year prognosis in acute coronary syndrome patients

Association between estimated cumulative LDL-C exposure and coronary artery disease severity and 2-year prognosis in acute coronary syndrome patients

Journal: Zhonghua xin xue guan bing za zhi

Published: March 17, 2025

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

Journal: Cancer management and research

Published: February 05, 2025

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.

Journal: Journal for immunotherapy of cancer

Published: January 19, 2025

Showing 1-12 of 135

Last Updated: 09/26/2026